U.S. License Holder:
Date of License:
ILARIS (canakinumab) is an interleukin-1 beta blocker indicated for the treatment of: Periodic Fever Syndromes:
Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older including: Familial Cold Autoinflammatory Syndrome (FCAS); Muckle-Wells Syndrome (MWS);
Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients;
Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients; and
Familial Mediterranean Fever (FMF) in adult and pediatric patients;
Active Still's disease, including Adult-Onset Still's Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.